WebOct 1, 2024 · THOR-707 is a reprogrammed, site-directed, single pegylated, recombinant human IL-2 (rIL-2) variant that lacks binding affinity for the α chain of the IL-2 receptor. Because THOR-707 has near-native binding affinity for the βγ chain of the IL-2 receptor, it produces an immune-active, CD8+ T effector-driven anti-tumor effect. WebOct 1, 2024 · While this is a reasonable strategy to avoid off-tumor side effects, clinical benefit has been seen with multiple untargeted IL-2 variant molecules such as NKTR-214, THOR-707, and ALKS-4230 23, 24 ...
Pegenzileukin - Sanofi - AdisInsight - Springer
WebApr 4, 2024 · Latest Information Update: 21 Nov 2024. Price : $50 *. Buy Profile. Adis is an information provider. We do not sell or distribute actual drugs. Final gross price and currency may vary according to local VAT and billing address. Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. WebOct 29, 2024 · Part 1 of the study will determine the recommended phase 2 dose (RP2D) of THOR-707 as a single agent and part 2 will determine the RP2D of THOR-707 in combination with a PD-1 inhibitor. nethertown railway station
Preliminary results from an open-label, multicenter ... - ResearchGate
WebJun 3, 2024 · SAR444245 (formerly known as THOR-707), Sanofi’s product candidate, is a differentiated IL-2 engineered for specificity and selectivity towards CD8+ T cells and Natural Killer (NK) cells. The molecule has a single, targeted PEG-moiety irreversibly linked to a novel amino acid inserted at a precise location. WebTHOR 707 - THOR-707, a “not-alpha†Synthorinâ„¢ of interleukin-2 (IL-2), for the treatment of solid tumors at the Society for Immunotherapy of Cancer (SITC) THOR-707, … WebSITC 2024 is the leading destination for scientific exchange, education and networking in the cancer immunotherapy field. ... Open-Label, Multicenter Phase 1/2 Dose Escalation and … i\u0027ll get right on that meme